ANPEP and breast cancer: Time-course inhibition experiments coupled to Western blot analysis confirmed that interfering with APC/C activation by Cdc20 in breast cancer cells treated with APN and Cbz-APN impaired the proteolytic degradation of the genuine APC/C substrates Cyclin B and Cdc20 (Figure 4B).